Global Meropenem Market

Meropenem Comprehensive Study by Application (Skin and Skin Structure Infection, Intra-abdominal infection, Meningitis, Nosocomial Infection, Others), End Users (Adult, Pediatric), Distribution Channel (Online, Offline), Strength (0.5g, 1.0g, 1.5g, 2.0g) Players and Region - Global Market Outlook to 2030

Meropenem Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 4.17%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Meropenem
Meropenem is a carbapenem antibiotic, which is active against gram-positive and gram-negative bacteria. Meropenem penetrate bacterial cells by interfering with the synthesis of vital cell wall components, which leads to cell death. Meropenem injection does not work for cold, flu or other viral infections. Taking antibiotics when they are not needed increases the risk of getting an infection which afterwards resists antibiotic treatment. Meropenem is an important option for the empirical treatment of serious bacterial infections in hospitalized patients.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR4.17%


The companies are exploring the market by adopting mergers & acquisitions, expansions and investments as their preferred strategies. Key players are exploring new geographies through expansions and acquisitions across the globe to avail competitive advantage through combined collaborations. Analyst at AMA Research estimates that Chinese and Japanese Players will contribute the maximum growth to Global Meropenem market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer (United States), Shenzhen Haibin Pharmaceutical (China), Fresenius Kabi (Canada), Novartis (Switzerland), Mylan (United States), Takeda (Japan), Sumitomo Pharmaceuticals (Japan), Sumitomo Dainippon Pharma Co. Ltd. (Japan), Astra Zeneca Pharma (India), Abbott (United States) and GE Healthcare (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Spectrum Chemical Manufacturing Corp (United States), Shijiazhuang Pharma (China) and Haikou Pharmaceutical Factory (China).

Segmentation Overview
AMA Research has segmented the market of Global Meropenem market by , Application (Skin and Skin Structure Infection, Intra-abdominal infection, Meningitis, Nosocomial Infection and Others) and Region.



On the basis of geography, the market of Meropenem has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Spain, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Users, the sub-segment i.e. Adult will boost the Meropenem market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Online will boost the Meropenem market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Strength, the sub-segment i.e. 0.5g will boost the Meropenem market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing use in empirical treatment and Effective in the treatment of bacterial meningitis

Market Growth Drivers:
Increasing awareness towards healthy lifestyle and Rising prevalence of skin infection across the globe

Challenges:
Easy availability of substitutes

Restraints:
Inappropriate use can affects adversely

Opportunities:
Increasing healthcare infrastructure in developing countries

Market Leaders and their expansionary development strategies
In October 2021, Tebipenem HBr (tebipenem pivoxil hydrobromide) was approved by the Food and Drug Administration (FDA) for the treatment of complex urinary tract infections (cUTI), including pyelonephritis, brought on by susceptible bacteria. The business said it would cooperate with the FDA throughout the NDA review procedure in preparation for the planned introduction of tebipenem HBr in the second half of 2022.
In January 2022, The New Drug Application (NDA) for the approval of tebipenem HBr oral tablets for the treatment of adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis, caused by susceptible microorganisms, was accepted for substantive review by the U.S. Food and Drug Administration (FDA).


Key Target Audience
Manufacturers of pharmaceutical drugs, Suppliers of pharmaceutical drugs, Wholesalers, distributers and retailers of pharmaceutical drugs, Healthcare industry, Research Firms and Governmental bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Skin and Skin Structure Infection
  • Intra-abdominal infection
  • Meningitis
  • Nosocomial Infection
  • Others
By End Users
  • Adult
  • Pediatric

By Distribution Channel
  • Online
  • Offline

By Strength
  • 0.5g
  • 1.0g
  • 1.5g
  • 2.0g

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Spain
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing awareness towards healthy lifestyle
      • 3.2.2. Rising prevalence of skin infection across the globe
    • 3.3. Market Challenges
      • 3.3.1. Easy availability of substitutes
    • 3.4. Market Trends
      • 3.4.1. Growing use in empirical treatment
      • 3.4.2. Effective in the treatment of bacterial meningitis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Meropenem, by Application, End Users, Distribution Channel, Strength and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Meropenem (Value)
      • 5.2.1. Global Meropenem by: Application (Value)
        • 5.2.1.1. Skin and Skin Structure Infection
        • 5.2.1.2. Intra-abdominal infection
        • 5.2.1.3. Meningitis
        • 5.2.1.4. Nosocomial Infection
        • 5.2.1.5. Others
      • 5.2.2. Global Meropenem by: End Users (Value)
        • 5.2.2.1. Adult
        • 5.2.2.2. Pediatric
      • 5.2.3. Global Meropenem by: Distribution Channel (Value)
        • 5.2.3.1. Online
        • 5.2.3.2. Offline
      • 5.2.4. Global Meropenem by: Strength (Value)
        • 5.2.4.1. 0.5g
        • 5.2.4.2. 1.0g
        • 5.2.4.3. 1.5g
        • 5.2.4.4. 2.0g
      • 5.2.5. Global Meropenem Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Spain
          • 5.2.5.3.6. Netherlands
          • 5.2.5.3.7. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Meropenem (Volume)
      • 5.3.1. Global Meropenem by: Application (Volume)
        • 5.3.1.1. Skin and Skin Structure Infection
        • 5.3.1.2. Intra-abdominal infection
        • 5.3.1.3. Meningitis
        • 5.3.1.4. Nosocomial Infection
        • 5.3.1.5. Others
      • 5.3.2. Global Meropenem by: End Users (Volume)
        • 5.3.2.1. Adult
        • 5.3.2.2. Pediatric
      • 5.3.3. Global Meropenem by: Distribution Channel (Volume)
        • 5.3.3.1. Online
        • 5.3.3.2. Offline
      • 5.3.4. Global Meropenem by: Strength (Volume)
        • 5.3.4.1. 0.5g
        • 5.3.4.2. 1.0g
        • 5.3.4.3. 1.5g
        • 5.3.4.4. 2.0g
      • 5.3.5. Global Meropenem Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Australia
          • 5.3.5.2.6. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Spain
          • 5.3.5.3.6. Netherlands
          • 5.3.5.3.7. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Meropenem (Price)
  • 6. Meropenem: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Shenzhen Haibin Pharmaceutical (China)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Fresenius Kabi (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mylan (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Takeda (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sumitomo Pharmaceuticals (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sumitomo Dainippon Pharma Co. Ltd. (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Astra Zeneca Pharma (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Abbott (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. GE Healthcare (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Meropenem Sale, by Application, End Users, Distribution Channel, Strength and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Meropenem (Value)
      • 7.2.1. Global Meropenem by: Application (Value)
        • 7.2.1.1. Skin and Skin Structure Infection
        • 7.2.1.2. Intra-abdominal infection
        • 7.2.1.3. Meningitis
        • 7.2.1.4. Nosocomial Infection
        • 7.2.1.5. Others
      • 7.2.2. Global Meropenem by: End Users (Value)
        • 7.2.2.1. Adult
        • 7.2.2.2. Pediatric
      • 7.2.3. Global Meropenem by: Distribution Channel (Value)
        • 7.2.3.1. Online
        • 7.2.3.2. Offline
      • 7.2.4. Global Meropenem by: Strength (Value)
        • 7.2.4.1. 0.5g
        • 7.2.4.2. 1.0g
        • 7.2.4.3. 1.5g
        • 7.2.4.4. 2.0g
      • 7.2.5. Global Meropenem Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Spain
          • 7.2.5.3.6. Netherlands
          • 7.2.5.3.7. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Meropenem (Volume)
      • 7.3.1. Global Meropenem by: Application (Volume)
        • 7.3.1.1. Skin and Skin Structure Infection
        • 7.3.1.2. Intra-abdominal infection
        • 7.3.1.3. Meningitis
        • 7.3.1.4. Nosocomial Infection
        • 7.3.1.5. Others
      • 7.3.2. Global Meropenem by: End Users (Volume)
        • 7.3.2.1. Adult
        • 7.3.2.2. Pediatric
      • 7.3.3. Global Meropenem by: Distribution Channel (Volume)
        • 7.3.3.1. Online
        • 7.3.3.2. Offline
      • 7.3.4. Global Meropenem by: Strength (Volume)
        • 7.3.4.1. 0.5g
        • 7.3.4.2. 1.0g
        • 7.3.4.3. 1.5g
        • 7.3.4.4. 2.0g
      • 7.3.5. Global Meropenem Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Australia
          • 7.3.5.2.6. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Spain
          • 7.3.5.3.6. Netherlands
          • 7.3.5.3.7. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Meropenem (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Meropenem: by Application(USD Million)
  • Table 2. Meropenem Skin and Skin Structure Infection , by Region USD Million (2018-2023)
  • Table 3. Meropenem Intra-abdominal infection , by Region USD Million (2018-2023)
  • Table 4. Meropenem Meningitis , by Region USD Million (2018-2023)
  • Table 5. Meropenem Nosocomial Infection , by Region USD Million (2018-2023)
  • Table 6. Meropenem Others , by Region USD Million (2018-2023)
  • Table 7. Meropenem: by End Users(USD Million)
  • Table 8. Meropenem Adult , by Region USD Million (2018-2023)
  • Table 9. Meropenem Pediatric , by Region USD Million (2018-2023)
  • Table 10. Meropenem: by Distribution Channel(USD Million)
  • Table 11. Meropenem Online , by Region USD Million (2018-2023)
  • Table 12. Meropenem Offline , by Region USD Million (2018-2023)
  • Table 13. Meropenem: by Strength(USD Million)
  • Table 14. Meropenem 0.5g , by Region USD Million (2018-2023)
  • Table 15. Meropenem 1.0g , by Region USD Million (2018-2023)
  • Table 16. Meropenem 1.5g , by Region USD Million (2018-2023)
  • Table 17. Meropenem 2.0g , by Region USD Million (2018-2023)
  • Table 18. South America Meropenem, by Country USD Million (2018-2023)
  • Table 19. South America Meropenem, by Application USD Million (2018-2023)
  • Table 20. South America Meropenem, by End Users USD Million (2018-2023)
  • Table 21. South America Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 22. South America Meropenem, by Strength USD Million (2018-2023)
  • Table 23. Brazil Meropenem, by Application USD Million (2018-2023)
  • Table 24. Brazil Meropenem, by End Users USD Million (2018-2023)
  • Table 25. Brazil Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 26. Brazil Meropenem, by Strength USD Million (2018-2023)
  • Table 27. Argentina Meropenem, by Application USD Million (2018-2023)
  • Table 28. Argentina Meropenem, by End Users USD Million (2018-2023)
  • Table 29. Argentina Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 30. Argentina Meropenem, by Strength USD Million (2018-2023)
  • Table 31. Rest of South America Meropenem, by Application USD Million (2018-2023)
  • Table 32. Rest of South America Meropenem, by End Users USD Million (2018-2023)
  • Table 33. Rest of South America Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 34. Rest of South America Meropenem, by Strength USD Million (2018-2023)
  • Table 35. Asia Pacific Meropenem, by Country USD Million (2018-2023)
  • Table 36. Asia Pacific Meropenem, by Application USD Million (2018-2023)
  • Table 37. Asia Pacific Meropenem, by End Users USD Million (2018-2023)
  • Table 38. Asia Pacific Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 39. Asia Pacific Meropenem, by Strength USD Million (2018-2023)
  • Table 40. China Meropenem, by Application USD Million (2018-2023)
  • Table 41. China Meropenem, by End Users USD Million (2018-2023)
  • Table 42. China Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 43. China Meropenem, by Strength USD Million (2018-2023)
  • Table 44. Japan Meropenem, by Application USD Million (2018-2023)
  • Table 45. Japan Meropenem, by End Users USD Million (2018-2023)
  • Table 46. Japan Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 47. Japan Meropenem, by Strength USD Million (2018-2023)
  • Table 48. India Meropenem, by Application USD Million (2018-2023)
  • Table 49. India Meropenem, by End Users USD Million (2018-2023)
  • Table 50. India Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 51. India Meropenem, by Strength USD Million (2018-2023)
  • Table 52. South Korea Meropenem, by Application USD Million (2018-2023)
  • Table 53. South Korea Meropenem, by End Users USD Million (2018-2023)
  • Table 54. South Korea Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 55. South Korea Meropenem, by Strength USD Million (2018-2023)
  • Table 56. Australia Meropenem, by Application USD Million (2018-2023)
  • Table 57. Australia Meropenem, by End Users USD Million (2018-2023)
  • Table 58. Australia Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 59. Australia Meropenem, by Strength USD Million (2018-2023)
  • Table 60. Rest of Asia-Pacific Meropenem, by Application USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Meropenem, by End Users USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Meropenem, by Strength USD Million (2018-2023)
  • Table 64. Europe Meropenem, by Country USD Million (2018-2023)
  • Table 65. Europe Meropenem, by Application USD Million (2018-2023)
  • Table 66. Europe Meropenem, by End Users USD Million (2018-2023)
  • Table 67. Europe Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 68. Europe Meropenem, by Strength USD Million (2018-2023)
  • Table 69. Germany Meropenem, by Application USD Million (2018-2023)
  • Table 70. Germany Meropenem, by End Users USD Million (2018-2023)
  • Table 71. Germany Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 72. Germany Meropenem, by Strength USD Million (2018-2023)
  • Table 73. France Meropenem, by Application USD Million (2018-2023)
  • Table 74. France Meropenem, by End Users USD Million (2018-2023)
  • Table 75. France Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 76. France Meropenem, by Strength USD Million (2018-2023)
  • Table 77. Italy Meropenem, by Application USD Million (2018-2023)
  • Table 78. Italy Meropenem, by End Users USD Million (2018-2023)
  • Table 79. Italy Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 80. Italy Meropenem, by Strength USD Million (2018-2023)
  • Table 81. United Kingdom Meropenem, by Application USD Million (2018-2023)
  • Table 82. United Kingdom Meropenem, by End Users USD Million (2018-2023)
  • Table 83. United Kingdom Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 84. United Kingdom Meropenem, by Strength USD Million (2018-2023)
  • Table 85. Spain Meropenem, by Application USD Million (2018-2023)
  • Table 86. Spain Meropenem, by End Users USD Million (2018-2023)
  • Table 87. Spain Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 88. Spain Meropenem, by Strength USD Million (2018-2023)
  • Table 89. Netherlands Meropenem, by Application USD Million (2018-2023)
  • Table 90. Netherlands Meropenem, by End Users USD Million (2018-2023)
  • Table 91. Netherlands Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 92. Netherlands Meropenem, by Strength USD Million (2018-2023)
  • Table 93. Rest of Europe Meropenem, by Application USD Million (2018-2023)
  • Table 94. Rest of Europe Meropenem, by End Users USD Million (2018-2023)
  • Table 95. Rest of Europe Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 96. Rest of Europe Meropenem, by Strength USD Million (2018-2023)
  • Table 97. MEA Meropenem, by Country USD Million (2018-2023)
  • Table 98. MEA Meropenem, by Application USD Million (2018-2023)
  • Table 99. MEA Meropenem, by End Users USD Million (2018-2023)
  • Table 100. MEA Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 101. MEA Meropenem, by Strength USD Million (2018-2023)
  • Table 102. Middle East Meropenem, by Application USD Million (2018-2023)
  • Table 103. Middle East Meropenem, by End Users USD Million (2018-2023)
  • Table 104. Middle East Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 105. Middle East Meropenem, by Strength USD Million (2018-2023)
  • Table 106. Africa Meropenem, by Application USD Million (2018-2023)
  • Table 107. Africa Meropenem, by End Users USD Million (2018-2023)
  • Table 108. Africa Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 109. Africa Meropenem, by Strength USD Million (2018-2023)
  • Table 110. North America Meropenem, by Country USD Million (2018-2023)
  • Table 111. North America Meropenem, by Application USD Million (2018-2023)
  • Table 112. North America Meropenem, by End Users USD Million (2018-2023)
  • Table 113. North America Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 114. North America Meropenem, by Strength USD Million (2018-2023)
  • Table 115. United States Meropenem, by Application USD Million (2018-2023)
  • Table 116. United States Meropenem, by End Users USD Million (2018-2023)
  • Table 117. United States Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 118. United States Meropenem, by Strength USD Million (2018-2023)
  • Table 119. Canada Meropenem, by Application USD Million (2018-2023)
  • Table 120. Canada Meropenem, by End Users USD Million (2018-2023)
  • Table 121. Canada Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 122. Canada Meropenem, by Strength USD Million (2018-2023)
  • Table 123. Mexico Meropenem, by Application USD Million (2018-2023)
  • Table 124. Mexico Meropenem, by End Users USD Million (2018-2023)
  • Table 125. Mexico Meropenem, by Distribution Channel USD Million (2018-2023)
  • Table 126. Mexico Meropenem, by Strength USD Million (2018-2023)
  • Table 127. Meropenem Sales: by Application(K Units)
  • Table 128. Meropenem Sales Skin and Skin Structure Infection , by Region K Units (2018-2023)
  • Table 129. Meropenem Sales Intra-abdominal infection , by Region K Units (2018-2023)
  • Table 130. Meropenem Sales Meningitis , by Region K Units (2018-2023)
  • Table 131. Meropenem Sales Nosocomial Infection , by Region K Units (2018-2023)
  • Table 132. Meropenem Sales Others , by Region K Units (2018-2023)
  • Table 133. Meropenem Sales: by End Users(K Units)
  • Table 134. Meropenem Sales Adult , by Region K Units (2018-2023)
  • Table 135. Meropenem Sales Pediatric , by Region K Units (2018-2023)
  • Table 136. Meropenem Sales: by Distribution Channel(K Units)
  • Table 137. Meropenem Sales Online , by Region K Units (2018-2023)
  • Table 138. Meropenem Sales Offline , by Region K Units (2018-2023)
  • Table 139. Meropenem Sales: by Strength(K Units)
  • Table 140. Meropenem Sales 0.5g , by Region K Units (2018-2023)
  • Table 141. Meropenem Sales 1.0g , by Region K Units (2018-2023)
  • Table 142. Meropenem Sales 1.5g , by Region K Units (2018-2023)
  • Table 143. Meropenem Sales 2.0g , by Region K Units (2018-2023)
  • Table 144. South America Meropenem Sales, by Country K Units (2018-2023)
  • Table 145. South America Meropenem Sales, by Application K Units (2018-2023)
  • Table 146. South America Meropenem Sales, by End Users K Units (2018-2023)
  • Table 147. South America Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 148. South America Meropenem Sales, by Strength K Units (2018-2023)
  • Table 149. Brazil Meropenem Sales, by Application K Units (2018-2023)
  • Table 150. Brazil Meropenem Sales, by End Users K Units (2018-2023)
  • Table 151. Brazil Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 152. Brazil Meropenem Sales, by Strength K Units (2018-2023)
  • Table 153. Argentina Meropenem Sales, by Application K Units (2018-2023)
  • Table 154. Argentina Meropenem Sales, by End Users K Units (2018-2023)
  • Table 155. Argentina Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 156. Argentina Meropenem Sales, by Strength K Units (2018-2023)
  • Table 157. Rest of South America Meropenem Sales, by Application K Units (2018-2023)
  • Table 158. Rest of South America Meropenem Sales, by End Users K Units (2018-2023)
  • Table 159. Rest of South America Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 160. Rest of South America Meropenem Sales, by Strength K Units (2018-2023)
  • Table 161. Asia Pacific Meropenem Sales, by Country K Units (2018-2023)
  • Table 162. Asia Pacific Meropenem Sales, by Application K Units (2018-2023)
  • Table 163. Asia Pacific Meropenem Sales, by End Users K Units (2018-2023)
  • Table 164. Asia Pacific Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 165. Asia Pacific Meropenem Sales, by Strength K Units (2018-2023)
  • Table 166. China Meropenem Sales, by Application K Units (2018-2023)
  • Table 167. China Meropenem Sales, by End Users K Units (2018-2023)
  • Table 168. China Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 169. China Meropenem Sales, by Strength K Units (2018-2023)
  • Table 170. Japan Meropenem Sales, by Application K Units (2018-2023)
  • Table 171. Japan Meropenem Sales, by End Users K Units (2018-2023)
  • Table 172. Japan Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 173. Japan Meropenem Sales, by Strength K Units (2018-2023)
  • Table 174. India Meropenem Sales, by Application K Units (2018-2023)
  • Table 175. India Meropenem Sales, by End Users K Units (2018-2023)
  • Table 176. India Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 177. India Meropenem Sales, by Strength K Units (2018-2023)
  • Table 178. South Korea Meropenem Sales, by Application K Units (2018-2023)
  • Table 179. South Korea Meropenem Sales, by End Users K Units (2018-2023)
  • Table 180. South Korea Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 181. South Korea Meropenem Sales, by Strength K Units (2018-2023)
  • Table 182. Australia Meropenem Sales, by Application K Units (2018-2023)
  • Table 183. Australia Meropenem Sales, by End Users K Units (2018-2023)
  • Table 184. Australia Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 185. Australia Meropenem Sales, by Strength K Units (2018-2023)
  • Table 186. Rest of Asia-Pacific Meropenem Sales, by Application K Units (2018-2023)
  • Table 187. Rest of Asia-Pacific Meropenem Sales, by End Users K Units (2018-2023)
  • Table 188. Rest of Asia-Pacific Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 189. Rest of Asia-Pacific Meropenem Sales, by Strength K Units (2018-2023)
  • Table 190. Europe Meropenem Sales, by Country K Units (2018-2023)
  • Table 191. Europe Meropenem Sales, by Application K Units (2018-2023)
  • Table 192. Europe Meropenem Sales, by End Users K Units (2018-2023)
  • Table 193. Europe Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 194. Europe Meropenem Sales, by Strength K Units (2018-2023)
  • Table 195. Germany Meropenem Sales, by Application K Units (2018-2023)
  • Table 196. Germany Meropenem Sales, by End Users K Units (2018-2023)
  • Table 197. Germany Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 198. Germany Meropenem Sales, by Strength K Units (2018-2023)
  • Table 199. France Meropenem Sales, by Application K Units (2018-2023)
  • Table 200. France Meropenem Sales, by End Users K Units (2018-2023)
  • Table 201. France Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 202. France Meropenem Sales, by Strength K Units (2018-2023)
  • Table 203. Italy Meropenem Sales, by Application K Units (2018-2023)
  • Table 204. Italy Meropenem Sales, by End Users K Units (2018-2023)
  • Table 205. Italy Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 206. Italy Meropenem Sales, by Strength K Units (2018-2023)
  • Table 207. United Kingdom Meropenem Sales, by Application K Units (2018-2023)
  • Table 208. United Kingdom Meropenem Sales, by End Users K Units (2018-2023)
  • Table 209. United Kingdom Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 210. United Kingdom Meropenem Sales, by Strength K Units (2018-2023)
  • Table 211. Spain Meropenem Sales, by Application K Units (2018-2023)
  • Table 212. Spain Meropenem Sales, by End Users K Units (2018-2023)
  • Table 213. Spain Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 214. Spain Meropenem Sales, by Strength K Units (2018-2023)
  • Table 215. Netherlands Meropenem Sales, by Application K Units (2018-2023)
  • Table 216. Netherlands Meropenem Sales, by End Users K Units (2018-2023)
  • Table 217. Netherlands Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 218. Netherlands Meropenem Sales, by Strength K Units (2018-2023)
  • Table 219. Rest of Europe Meropenem Sales, by Application K Units (2018-2023)
  • Table 220. Rest of Europe Meropenem Sales, by End Users K Units (2018-2023)
  • Table 221. Rest of Europe Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 222. Rest of Europe Meropenem Sales, by Strength K Units (2018-2023)
  • Table 223. MEA Meropenem Sales, by Country K Units (2018-2023)
  • Table 224. MEA Meropenem Sales, by Application K Units (2018-2023)
  • Table 225. MEA Meropenem Sales, by End Users K Units (2018-2023)
  • Table 226. MEA Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 227. MEA Meropenem Sales, by Strength K Units (2018-2023)
  • Table 228. Middle East Meropenem Sales, by Application K Units (2018-2023)
  • Table 229. Middle East Meropenem Sales, by End Users K Units (2018-2023)
  • Table 230. Middle East Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 231. Middle East Meropenem Sales, by Strength K Units (2018-2023)
  • Table 232. Africa Meropenem Sales, by Application K Units (2018-2023)
  • Table 233. Africa Meropenem Sales, by End Users K Units (2018-2023)
  • Table 234. Africa Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 235. Africa Meropenem Sales, by Strength K Units (2018-2023)
  • Table 236. North America Meropenem Sales, by Country K Units (2018-2023)
  • Table 237. North America Meropenem Sales, by Application K Units (2018-2023)
  • Table 238. North America Meropenem Sales, by End Users K Units (2018-2023)
  • Table 239. North America Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 240. North America Meropenem Sales, by Strength K Units (2018-2023)
  • Table 241. United States Meropenem Sales, by Application K Units (2018-2023)
  • Table 242. United States Meropenem Sales, by End Users K Units (2018-2023)
  • Table 243. United States Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 244. United States Meropenem Sales, by Strength K Units (2018-2023)
  • Table 245. Canada Meropenem Sales, by Application K Units (2018-2023)
  • Table 246. Canada Meropenem Sales, by End Users K Units (2018-2023)
  • Table 247. Canada Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 248. Canada Meropenem Sales, by Strength K Units (2018-2023)
  • Table 249. Mexico Meropenem Sales, by Application K Units (2018-2023)
  • Table 250. Mexico Meropenem Sales, by End Users K Units (2018-2023)
  • Table 251. Mexico Meropenem Sales, by Distribution Channel K Units (2018-2023)
  • Table 252. Mexico Meropenem Sales, by Strength K Units (2018-2023)
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Meropenem: by Application(USD Million)
  • Table 265. Meropenem Skin and Skin Structure Infection , by Region USD Million (2025-2030)
  • Table 266. Meropenem Intra-abdominal infection , by Region USD Million (2025-2030)
  • Table 267. Meropenem Meningitis , by Region USD Million (2025-2030)
  • Table 268. Meropenem Nosocomial Infection , by Region USD Million (2025-2030)
  • Table 269. Meropenem Others , by Region USD Million (2025-2030)
  • Table 270. Meropenem: by End Users(USD Million)
  • Table 271. Meropenem Adult , by Region USD Million (2025-2030)
  • Table 272. Meropenem Pediatric , by Region USD Million (2025-2030)
  • Table 273. Meropenem: by Distribution Channel(USD Million)
  • Table 274. Meropenem Online , by Region USD Million (2025-2030)
  • Table 275. Meropenem Offline , by Region USD Million (2025-2030)
  • Table 276. Meropenem: by Strength(USD Million)
  • Table 277. Meropenem 0.5g , by Region USD Million (2025-2030)
  • Table 278. Meropenem 1.0g , by Region USD Million (2025-2030)
  • Table 279. Meropenem 1.5g , by Region USD Million (2025-2030)
  • Table 280. Meropenem 2.0g , by Region USD Million (2025-2030)
  • Table 281. South America Meropenem, by Country USD Million (2025-2030)
  • Table 282. South America Meropenem, by Application USD Million (2025-2030)
  • Table 283. South America Meropenem, by End Users USD Million (2025-2030)
  • Table 284. South America Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 285. South America Meropenem, by Strength USD Million (2025-2030)
  • Table 286. Brazil Meropenem, by Application USD Million (2025-2030)
  • Table 287. Brazil Meropenem, by End Users USD Million (2025-2030)
  • Table 288. Brazil Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 289. Brazil Meropenem, by Strength USD Million (2025-2030)
  • Table 290. Argentina Meropenem, by Application USD Million (2025-2030)
  • Table 291. Argentina Meropenem, by End Users USD Million (2025-2030)
  • Table 292. Argentina Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 293. Argentina Meropenem, by Strength USD Million (2025-2030)
  • Table 294. Rest of South America Meropenem, by Application USD Million (2025-2030)
  • Table 295. Rest of South America Meropenem, by End Users USD Million (2025-2030)
  • Table 296. Rest of South America Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 297. Rest of South America Meropenem, by Strength USD Million (2025-2030)
  • Table 298. Asia Pacific Meropenem, by Country USD Million (2025-2030)
  • Table 299. Asia Pacific Meropenem, by Application USD Million (2025-2030)
  • Table 300. Asia Pacific Meropenem, by End Users USD Million (2025-2030)
  • Table 301. Asia Pacific Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 302. Asia Pacific Meropenem, by Strength USD Million (2025-2030)
  • Table 303. China Meropenem, by Application USD Million (2025-2030)
  • Table 304. China Meropenem, by End Users USD Million (2025-2030)
  • Table 305. China Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 306. China Meropenem, by Strength USD Million (2025-2030)
  • Table 307. Japan Meropenem, by Application USD Million (2025-2030)
  • Table 308. Japan Meropenem, by End Users USD Million (2025-2030)
  • Table 309. Japan Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 310. Japan Meropenem, by Strength USD Million (2025-2030)
  • Table 311. India Meropenem, by Application USD Million (2025-2030)
  • Table 312. India Meropenem, by End Users USD Million (2025-2030)
  • Table 313. India Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 314. India Meropenem, by Strength USD Million (2025-2030)
  • Table 315. South Korea Meropenem, by Application USD Million (2025-2030)
  • Table 316. South Korea Meropenem, by End Users USD Million (2025-2030)
  • Table 317. South Korea Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 318. South Korea Meropenem, by Strength USD Million (2025-2030)
  • Table 319. Australia Meropenem, by Application USD Million (2025-2030)
  • Table 320. Australia Meropenem, by End Users USD Million (2025-2030)
  • Table 321. Australia Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 322. Australia Meropenem, by Strength USD Million (2025-2030)
  • Table 323. Rest of Asia-Pacific Meropenem, by Application USD Million (2025-2030)
  • Table 324. Rest of Asia-Pacific Meropenem, by End Users USD Million (2025-2030)
  • Table 325. Rest of Asia-Pacific Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 326. Rest of Asia-Pacific Meropenem, by Strength USD Million (2025-2030)
  • Table 327. Europe Meropenem, by Country USD Million (2025-2030)
  • Table 328. Europe Meropenem, by Application USD Million (2025-2030)
  • Table 329. Europe Meropenem, by End Users USD Million (2025-2030)
  • Table 330. Europe Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 331. Europe Meropenem, by Strength USD Million (2025-2030)
  • Table 332. Germany Meropenem, by Application USD Million (2025-2030)
  • Table 333. Germany Meropenem, by End Users USD Million (2025-2030)
  • Table 334. Germany Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 335. Germany Meropenem, by Strength USD Million (2025-2030)
  • Table 336. France Meropenem, by Application USD Million (2025-2030)
  • Table 337. France Meropenem, by End Users USD Million (2025-2030)
  • Table 338. France Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 339. France Meropenem, by Strength USD Million (2025-2030)
  • Table 340. Italy Meropenem, by Application USD Million (2025-2030)
  • Table 341. Italy Meropenem, by End Users USD Million (2025-2030)
  • Table 342. Italy Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 343. Italy Meropenem, by Strength USD Million (2025-2030)
  • Table 344. United Kingdom Meropenem, by Application USD Million (2025-2030)
  • Table 345. United Kingdom Meropenem, by End Users USD Million (2025-2030)
  • Table 346. United Kingdom Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 347. United Kingdom Meropenem, by Strength USD Million (2025-2030)
  • Table 348. Spain Meropenem, by Application USD Million (2025-2030)
  • Table 349. Spain Meropenem, by End Users USD Million (2025-2030)
  • Table 350. Spain Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 351. Spain Meropenem, by Strength USD Million (2025-2030)
  • Table 352. Netherlands Meropenem, by Application USD Million (2025-2030)
  • Table 353. Netherlands Meropenem, by End Users USD Million (2025-2030)
  • Table 354. Netherlands Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 355. Netherlands Meropenem, by Strength USD Million (2025-2030)
  • Table 356. Rest of Europe Meropenem, by Application USD Million (2025-2030)
  • Table 357. Rest of Europe Meropenem, by End Users USD Million (2025-2030)
  • Table 358. Rest of Europe Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 359. Rest of Europe Meropenem, by Strength USD Million (2025-2030)
  • Table 360. MEA Meropenem, by Country USD Million (2025-2030)
  • Table 361. MEA Meropenem, by Application USD Million (2025-2030)
  • Table 362. MEA Meropenem, by End Users USD Million (2025-2030)
  • Table 363. MEA Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 364. MEA Meropenem, by Strength USD Million (2025-2030)
  • Table 365. Middle East Meropenem, by Application USD Million (2025-2030)
  • Table 366. Middle East Meropenem, by End Users USD Million (2025-2030)
  • Table 367. Middle East Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 368. Middle East Meropenem, by Strength USD Million (2025-2030)
  • Table 369. Africa Meropenem, by Application USD Million (2025-2030)
  • Table 370. Africa Meropenem, by End Users USD Million (2025-2030)
  • Table 371. Africa Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 372. Africa Meropenem, by Strength USD Million (2025-2030)
  • Table 373. North America Meropenem, by Country USD Million (2025-2030)
  • Table 374. North America Meropenem, by Application USD Million (2025-2030)
  • Table 375. North America Meropenem, by End Users USD Million (2025-2030)
  • Table 376. North America Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 377. North America Meropenem, by Strength USD Million (2025-2030)
  • Table 378. United States Meropenem, by Application USD Million (2025-2030)
  • Table 379. United States Meropenem, by End Users USD Million (2025-2030)
  • Table 380. United States Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 381. United States Meropenem, by Strength USD Million (2025-2030)
  • Table 382. Canada Meropenem, by Application USD Million (2025-2030)
  • Table 383. Canada Meropenem, by End Users USD Million (2025-2030)
  • Table 384. Canada Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 385. Canada Meropenem, by Strength USD Million (2025-2030)
  • Table 386. Mexico Meropenem, by Application USD Million (2025-2030)
  • Table 387. Mexico Meropenem, by End Users USD Million (2025-2030)
  • Table 388. Mexico Meropenem, by Distribution Channel USD Million (2025-2030)
  • Table 389. Mexico Meropenem, by Strength USD Million (2025-2030)
  • Table 390. Meropenem Sales: by Application(K Units)
  • Table 391. Meropenem Sales Skin and Skin Structure Infection , by Region K Units (2025-2030)
  • Table 392. Meropenem Sales Intra-abdominal infection , by Region K Units (2025-2030)
  • Table 393. Meropenem Sales Meningitis , by Region K Units (2025-2030)
  • Table 394. Meropenem Sales Nosocomial Infection , by Region K Units (2025-2030)
  • Table 395. Meropenem Sales Others , by Region K Units (2025-2030)
  • Table 396. Meropenem Sales: by End Users(K Units)
  • Table 397. Meropenem Sales Adult , by Region K Units (2025-2030)
  • Table 398. Meropenem Sales Pediatric , by Region K Units (2025-2030)
  • Table 399. Meropenem Sales: by Distribution Channel(K Units)
  • Table 400. Meropenem Sales Online , by Region K Units (2025-2030)
  • Table 401. Meropenem Sales Offline , by Region K Units (2025-2030)
  • Table 402. Meropenem Sales: by Strength(K Units)
  • Table 403. Meropenem Sales 0.5g , by Region K Units (2025-2030)
  • Table 404. Meropenem Sales 1.0g , by Region K Units (2025-2030)
  • Table 405. Meropenem Sales 1.5g , by Region K Units (2025-2030)
  • Table 406. Meropenem Sales 2.0g , by Region K Units (2025-2030)
  • Table 407. South America Meropenem Sales, by Country K Units (2025-2030)
  • Table 408. South America Meropenem Sales, by Application K Units (2025-2030)
  • Table 409. South America Meropenem Sales, by End Users K Units (2025-2030)
  • Table 410. South America Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 411. South America Meropenem Sales, by Strength K Units (2025-2030)
  • Table 412. Brazil Meropenem Sales, by Application K Units (2025-2030)
  • Table 413. Brazil Meropenem Sales, by End Users K Units (2025-2030)
  • Table 414. Brazil Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 415. Brazil Meropenem Sales, by Strength K Units (2025-2030)
  • Table 416. Argentina Meropenem Sales, by Application K Units (2025-2030)
  • Table 417. Argentina Meropenem Sales, by End Users K Units (2025-2030)
  • Table 418. Argentina Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 419. Argentina Meropenem Sales, by Strength K Units (2025-2030)
  • Table 420. Rest of South America Meropenem Sales, by Application K Units (2025-2030)
  • Table 421. Rest of South America Meropenem Sales, by End Users K Units (2025-2030)
  • Table 422. Rest of South America Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 423. Rest of South America Meropenem Sales, by Strength K Units (2025-2030)
  • Table 424. Asia Pacific Meropenem Sales, by Country K Units (2025-2030)
  • Table 425. Asia Pacific Meropenem Sales, by Application K Units (2025-2030)
  • Table 426. Asia Pacific Meropenem Sales, by End Users K Units (2025-2030)
  • Table 427. Asia Pacific Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 428. Asia Pacific Meropenem Sales, by Strength K Units (2025-2030)
  • Table 429. China Meropenem Sales, by Application K Units (2025-2030)
  • Table 430. China Meropenem Sales, by End Users K Units (2025-2030)
  • Table 431. China Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 432. China Meropenem Sales, by Strength K Units (2025-2030)
  • Table 433. Japan Meropenem Sales, by Application K Units (2025-2030)
  • Table 434. Japan Meropenem Sales, by End Users K Units (2025-2030)
  • Table 435. Japan Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 436. Japan Meropenem Sales, by Strength K Units (2025-2030)
  • Table 437. India Meropenem Sales, by Application K Units (2025-2030)
  • Table 438. India Meropenem Sales, by End Users K Units (2025-2030)
  • Table 439. India Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 440. India Meropenem Sales, by Strength K Units (2025-2030)
  • Table 441. South Korea Meropenem Sales, by Application K Units (2025-2030)
  • Table 442. South Korea Meropenem Sales, by End Users K Units (2025-2030)
  • Table 443. South Korea Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 444. South Korea Meropenem Sales, by Strength K Units (2025-2030)
  • Table 445. Australia Meropenem Sales, by Application K Units (2025-2030)
  • Table 446. Australia Meropenem Sales, by End Users K Units (2025-2030)
  • Table 447. Australia Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 448. Australia Meropenem Sales, by Strength K Units (2025-2030)
  • Table 449. Rest of Asia-Pacific Meropenem Sales, by Application K Units (2025-2030)
  • Table 450. Rest of Asia-Pacific Meropenem Sales, by End Users K Units (2025-2030)
  • Table 451. Rest of Asia-Pacific Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 452. Rest of Asia-Pacific Meropenem Sales, by Strength K Units (2025-2030)
  • Table 453. Europe Meropenem Sales, by Country K Units (2025-2030)
  • Table 454. Europe Meropenem Sales, by Application K Units (2025-2030)
  • Table 455. Europe Meropenem Sales, by End Users K Units (2025-2030)
  • Table 456. Europe Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 457. Europe Meropenem Sales, by Strength K Units (2025-2030)
  • Table 458. Germany Meropenem Sales, by Application K Units (2025-2030)
  • Table 459. Germany Meropenem Sales, by End Users K Units (2025-2030)
  • Table 460. Germany Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 461. Germany Meropenem Sales, by Strength K Units (2025-2030)
  • Table 462. France Meropenem Sales, by Application K Units (2025-2030)
  • Table 463. France Meropenem Sales, by End Users K Units (2025-2030)
  • Table 464. France Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 465. France Meropenem Sales, by Strength K Units (2025-2030)
  • Table 466. Italy Meropenem Sales, by Application K Units (2025-2030)
  • Table 467. Italy Meropenem Sales, by End Users K Units (2025-2030)
  • Table 468. Italy Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 469. Italy Meropenem Sales, by Strength K Units (2025-2030)
  • Table 470. United Kingdom Meropenem Sales, by Application K Units (2025-2030)
  • Table 471. United Kingdom Meropenem Sales, by End Users K Units (2025-2030)
  • Table 472. United Kingdom Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 473. United Kingdom Meropenem Sales, by Strength K Units (2025-2030)
  • Table 474. Spain Meropenem Sales, by Application K Units (2025-2030)
  • Table 475. Spain Meropenem Sales, by End Users K Units (2025-2030)
  • Table 476. Spain Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 477. Spain Meropenem Sales, by Strength K Units (2025-2030)
  • Table 478. Netherlands Meropenem Sales, by Application K Units (2025-2030)
  • Table 479. Netherlands Meropenem Sales, by End Users K Units (2025-2030)
  • Table 480. Netherlands Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 481. Netherlands Meropenem Sales, by Strength K Units (2025-2030)
  • Table 482. Rest of Europe Meropenem Sales, by Application K Units (2025-2030)
  • Table 483. Rest of Europe Meropenem Sales, by End Users K Units (2025-2030)
  • Table 484. Rest of Europe Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 485. Rest of Europe Meropenem Sales, by Strength K Units (2025-2030)
  • Table 486. MEA Meropenem Sales, by Country K Units (2025-2030)
  • Table 487. MEA Meropenem Sales, by Application K Units (2025-2030)
  • Table 488. MEA Meropenem Sales, by End Users K Units (2025-2030)
  • Table 489. MEA Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 490. MEA Meropenem Sales, by Strength K Units (2025-2030)
  • Table 491. Middle East Meropenem Sales, by Application K Units (2025-2030)
  • Table 492. Middle East Meropenem Sales, by End Users K Units (2025-2030)
  • Table 493. Middle East Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 494. Middle East Meropenem Sales, by Strength K Units (2025-2030)
  • Table 495. Africa Meropenem Sales, by Application K Units (2025-2030)
  • Table 496. Africa Meropenem Sales, by End Users K Units (2025-2030)
  • Table 497. Africa Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 498. Africa Meropenem Sales, by Strength K Units (2025-2030)
  • Table 499. North America Meropenem Sales, by Country K Units (2025-2030)
  • Table 500. North America Meropenem Sales, by Application K Units (2025-2030)
  • Table 501. North America Meropenem Sales, by End Users K Units (2025-2030)
  • Table 502. North America Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 503. North America Meropenem Sales, by Strength K Units (2025-2030)
  • Table 504. United States Meropenem Sales, by Application K Units (2025-2030)
  • Table 505. United States Meropenem Sales, by End Users K Units (2025-2030)
  • Table 506. United States Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 507. United States Meropenem Sales, by Strength K Units (2025-2030)
  • Table 508. Canada Meropenem Sales, by Application K Units (2025-2030)
  • Table 509. Canada Meropenem Sales, by End Users K Units (2025-2030)
  • Table 510. Canada Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 511. Canada Meropenem Sales, by Strength K Units (2025-2030)
  • Table 512. Mexico Meropenem Sales, by Application K Units (2025-2030)
  • Table 513. Mexico Meropenem Sales, by End Users K Units (2025-2030)
  • Table 514. Mexico Meropenem Sales, by Distribution Channel K Units (2025-2030)
  • Table 515. Mexico Meropenem Sales, by Strength K Units (2025-2030)
  • Table 516. Research Programs/Design for This Report
  • Table 517. Key Data Information from Secondary Sources
  • Table 518. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Meropenem: by Application USD Million (2018-2023)
  • Figure 5. Global Meropenem: by End Users USD Million (2018-2023)
  • Figure 6. Global Meropenem: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Meropenem: by Strength USD Million (2018-2023)
  • Figure 8. South America Meropenem Share (%), by Country
  • Figure 9. Asia Pacific Meropenem Share (%), by Country
  • Figure 10. Europe Meropenem Share (%), by Country
  • Figure 11. MEA Meropenem Share (%), by Country
  • Figure 12. North America Meropenem Share (%), by Country
  • Figure 13. Global Meropenem: by Application K Units (2018-2023)
  • Figure 14. Global Meropenem: by End Users K Units (2018-2023)
  • Figure 15. Global Meropenem: by Distribution Channel K Units (2018-2023)
  • Figure 16. Global Meropenem: by Strength K Units (2018-2023)
  • Figure 17. South America Meropenem Share (%), by Country
  • Figure 18. Asia Pacific Meropenem Share (%), by Country
  • Figure 19. Europe Meropenem Share (%), by Country
  • Figure 20. MEA Meropenem Share (%), by Country
  • Figure 21. North America Meropenem Share (%), by Country
  • Figure 22. Global Meropenem share by Players 2023 (%)
  • Figure 23. Global Meropenem share by Players (Top 3) 2023(%)
  • Figure 24. Global Meropenem share by Players (Top 5) 2023(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer (United States) Revenue: by Geography 2023
  • Figure 28. Shenzhen Haibin Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 29. Shenzhen Haibin Pharmaceutical (China) Revenue: by Geography 2023
  • Figure 30. Fresenius Kabi (Canada) Revenue, Net Income and Gross profit
  • Figure 31. Fresenius Kabi (Canada) Revenue: by Geography 2023
  • Figure 32. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 34. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 35. Mylan (United States) Revenue: by Geography 2023
  • Figure 36. Takeda (Japan) Revenue, Net Income and Gross profit
  • Figure 37. Takeda (Japan) Revenue: by Geography 2023
  • Figure 38. Sumitomo Pharmaceuticals (Japan) Revenue, Net Income and Gross profit
  • Figure 39. Sumitomo Pharmaceuticals (Japan) Revenue: by Geography 2023
  • Figure 40. Sumitomo Dainippon Pharma Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 41. Sumitomo Dainippon Pharma Co. Ltd. (Japan) Revenue: by Geography 2023
  • Figure 42. Astra Zeneca Pharma (India) Revenue, Net Income and Gross profit
  • Figure 43. Astra Zeneca Pharma (India) Revenue: by Geography 2023
  • Figure 44. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 45. Abbott (United States) Revenue: by Geography 2023
  • Figure 46. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 47. GE Healthcare (United States) Revenue: by Geography 2023
  • Figure 48. Global Meropenem: by Application USD Million (2025-2030)
  • Figure 49. Global Meropenem: by End Users USD Million (2025-2030)
  • Figure 50. Global Meropenem: by Distribution Channel USD Million (2025-2030)
  • Figure 51. Global Meropenem: by Strength USD Million (2025-2030)
  • Figure 52. South America Meropenem Share (%), by Country
  • Figure 53. Asia Pacific Meropenem Share (%), by Country
  • Figure 54. Europe Meropenem Share (%), by Country
  • Figure 55. MEA Meropenem Share (%), by Country
  • Figure 56. North America Meropenem Share (%), by Country
  • Figure 57. Global Meropenem: by Application K Units (2025-2030)
  • Figure 58. Global Meropenem: by End Users K Units (2025-2030)
  • Figure 59. Global Meropenem: by Distribution Channel K Units (2025-2030)
  • Figure 60. Global Meropenem: by Strength K Units (2025-2030)
  • Figure 61. South America Meropenem Share (%), by Country
  • Figure 62. Asia Pacific Meropenem Share (%), by Country
  • Figure 63. Europe Meropenem Share (%), by Country
  • Figure 64. MEA Meropenem Share (%), by Country
  • Figure 65. North America Meropenem Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Shenzhen Haibin Pharmaceutical (China)
  • Fresenius Kabi (Canada)
  • Novartis (Switzerland)
  • Mylan (United States)
  • Takeda (Japan)
  • Sumitomo Pharmaceuticals (Japan)
  • Sumitomo Dainippon Pharma Co. Ltd. (Japan)
  • Astra Zeneca Pharma (India)
  • Abbott (United States)
  • GE Healthcare (United States)
Additional players considered in the study are as follows:
Spectrum Chemical Manufacturing Corp (United States) , Shijiazhuang Pharma (China) , Haikou Pharmaceutical Factory (China)
Select User Access Type

Key Highlights of Report


Mar 2024 246 Pages 91 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Meropenem Market Quantitative research analysis
Global Meropenem Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer (United States), Shenzhen Haibin Pharmaceutical (China), Fresenius Kabi (Canada), Novartis (Switzerland), Mylan (United States), Takeda (Japan), Sumitomo Pharmaceuticals (Japan), Sumitomo Dainippon Pharma Co. Ltd. (Japan), Astra Zeneca Pharma (India), Abbott (United States) and GE Healthcare (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing use in empirical treatment " is seen as one of major influencing trends for Meropenem Market during projected period 2023-2030.
The Meropenem market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Meropenem Market Report?

Have a Query? Click Here

Other Related Reports

Cardiac Troponin Comprehensive Study by Type (CTn T, CTn I, TnC), Application (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others Applications), End User (Laboratory Tes...
$ 3350
Branded Generics Comprehensive Study by Type (Value Added Branded Generics, Trade (Brand) Named Generics), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores, Others)...
$ 3650
Insulin Glargine Comprehensive Study by Application (Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)), Forms (Liquid, Tablet, Syrup, Cream, Gel), Side Effect (Rash, Hives, Itching, Wheezing), Distribut...
$ 3800
Topical Pain Relief Comprehensive Study by Type (Prescription Pain Relief Products, Over-the-counter (OTC) Pain Relief Products), Application (Pets, Mammals, Farm Animals), Distribution Channel (Phar...
$ 3650
Atenolol Tablets Comprehensive Study by Application (Hypertension, Angina, Arrhythmias), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Prescription Mode (Prescript...
$ 3450
TB Vaccines Comprehensive Study by Type (Attenuated, Booster), Application (Hospitals, Clinical Labs, Pharmaceuticals), Distribution Channel (Online, Offline), Age Group (Pediatric, 16 Years – 35 Yea...
$ 3800